title: Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
abstract: Busulphan pharmacokinetics were investigated in 20 children, who underwent bone marrow transplantation for either leukemia or inherited disorders. Busulphan (1.90-6.02 mg/kg/day) was administered orally as a single dose or twice daily. Busulphan kinetics were found to be linear within the studied range. Children with inherited disorders eliminated busulphan significantly faster after the first and the last dose with half-lives (t1/2) of 1.93 and 1.71 h, respectively compared to children with leukemia (3.16 and 2.70 h, respectively). The area under plasma concentration curves (AUCs, corrected for mg/kg) as an expression for the systemic exposure of busulphan were significantly higher in children with leukemia, 22.4 and 19.04 mumol/l.h (5527 and 4690 ng.h.ml-1) after the first and the last dose, respectively, compared to 11.2 and 8.2 mumol/l.h (2768 and 2029 ng.h.ml-1) found in children with inherited disorders. The present results confirm those reported by others, ie busulphan pharmacokinetics can be influenced by the underlying disease and its status. Our population pharmacokinetic analysis showed a negative correlation between the weight corrected clearance and the age in both groups of children. However, clearance was about 42% higher in children with inherited disorders compared to those with leukemia. To estimate AUC for the first dose, we evaluated a limited sampling model based on three concentrations (1, 3 and 6 h). A high correlation (r = 0.998, P < 0.0001, n = 40) between the estimated and the determined AUC was found. The present model is reliable and adequate for studying more patients, with a long-term follow-up combined with drug monitoring in correlation with drug efficacy and toxicity to define the optimal busulphan dosage required.
authors.affiliation: Karolinska Pharmacy, Research Department, Stockholm, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Hassan
authors.forename: A
authors.initials: A
authors.lastname: Fasth
authors.forename: B
authors.initials: B
authors.lastname: Gerritsen
authors.forename: A
authors.initials: A
authors.lastname: Haraldsson
authors.forename: Z
authors.initials: Z
authors.lastname: Syrůcková
authors.forename: H
authors.initials: H
authors.lastname: van den Berg
authors.forename: M
authors.initials: M
authors.lastname: Sandström
authors.forename: M
authors.initials: M
authors.lastname: Karlsson
authors.forename: S
authors.initials: S
authors.lastname: Kumlien
authors.forename: J
authors.initials: J
authors.lastname: Vossen
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D000013:Congenital Abnormalities / Q000628:therapy*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007223:Infant; D007938:Leukemia / Q000628:therapy*
chemical_list: D007166:Immunosuppressive Agents; D002066:Busulfan